Market Cap 328.63M
Revenue (ttm) 0.00
Net Income (ttm) -47.05M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 195,000
Avg Vol 288,100
Day's Range N/A - N/A
Shares Out 64.06M
Stochastic %K 77%
Beta 0.85
Analysts Sell
Price Target $6.00

Company Profile

Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the drug research and development to create new therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02), a galectin-3 inhibitor, which is in Phase 2b/3 clinical trial to prevent esophageal varices in patient with non-alcoholic steatohepatitis cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and he...

Industry: Biotechnology
Sector: Healthcare
Phone: 678 620 3186
Address:
4960 Peachtree Industrial Boulevard, Suite 240, Norcross, United States
dmacw
dmacw Oct. 25 at 11:45 PM
$GALT When does the SEC embargo come off?
0 · Reply
ThomasLD
ThomasLD Oct. 25 at 7:22 PM
$GALT Great summary from Expharm. @beacher @Expharmaguy They will definitely meet with FDA per CFO Jack C. This company will likely be sold eventually. Just HOLD your shares if you already bought.
0 · Reply
beacher
beacher Oct. 25 at 5:20 PM
$GALT Hey all. I’ve heard some buzz about a potential buyout, which is why I’m digging into this. But based on the 10-Q for the quarter ended June 30, 2025, and the 2025 Proxy Statement, there’s no hint of a buyout. The financials show a cash balance of $13.771K and ongoing R&D expenses, while the Proxy focuses on the virtual annual meeting and routine shareholder votes. Now, regarding the vesting details for those 504,000 RSUs granted to employees: They’ll vest 100% either when the company enters a partnership or by December 31, 2025—whichever comes first! So the filing is suggesting they’re planning for the year-end vesting unless a partnership speeds things up. It’s a great incentive for the crew, but no immediate deal seems on the horizon! Despite that, it seems GLAT is an interesting investment - I´ll put it on my list.
2 · Reply
th3_fail_k1ng
th3_fail_k1ng Oct. 25 at 4:03 PM
$GALT well that's interesting, I just realized that astrazeneca's CEO, their mash division head, and an AstraZeneca headhunter have been liking our CMOS posts since the Koh conference. They have the money to buy us and they're headquartered in the EU as well and they hit above their weight class for buyouts? Plenty of options @gscdefense
2 · Reply
LiquidThetaLEAPS
LiquidThetaLEAPS Oct. 25 at 2:49 PM
LiquidTheta® LEAPS LIVE Actionable Alert Asset: $GALT Current Share Price: $5.23 Contracts: $GALT January 15, 2027 $8 Calls Scale in: $2.16- $2.64 Scale out: $3.36-$4.32 Can Easily Capture: 60% ROI Blended DTE: 447 Days | Join Elites here: https://liquidtheta.com
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Oct. 25 at 1:49 PM
Enter: $GALT Calls Strike Price: $8 Expiry Date: NOV 21 2025 Buy in Price: $0.22 - $0.25 Sell Price: $0.33 Profit : +49% (Turn every $1 into $1.49) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us/
0 · Reply
MoneyInc
MoneyInc Oct. 25 at 12:45 PM
$GALT AASLD approaches. End of year approaches. Get ready to absolutely rip!!
0 · Reply
ThomasLD
ThomasLD Oct. 25 at 12:21 PM
$GALT Since Belapectin is so complex to bid on, I am wondering we may get cash plus CVR for $18B x 2 ~ $36B?
1 · Reply
Indibviduate1
Indibviduate1 Oct. 25 at 7:42 AM
$GALT Interesting to note that Nordic bioscience supported Novo Nordisk by measuring fibroblast activity via pro c3. Wonder if they’re doing the same for us. “Nordic Bioscience would like to congratulate Novo Nordisk for the FDA approval of the first GLP-1 based therapy, semaglutide, for the treatment of adult patients living with MASH. We at Nordic Bioscience are proud to have supported the phase III “ESSENCE” trial, measuring our fibroblast activity marker, PRO-C3 in our Copenhagen based CAP/CLIA-certified laboratory. The “ESSENCE” trial presented data showing that semaglutide was able to reduce PRO-C3 by 17% compared to placebo treated patients. This is also an opportune time, as we are hosting a webinar on PRO-C3 that will delve into the PRO-C3 journey, its use cases, and its effect on world leading clinical trials.”
1 · Reply
Indibviduate1
Indibviduate1 Oct. 25 at 6:55 AM
$GALT so Nordic says that deactivating fibroblasts can significantly improve clinical outcomes for over 100 diseases. Well inhibiting galectin 3 is a proven way to deactivate fibroblasts. Do we have an incredibly valuable drug here for multiple applications?
2 · Reply
Latest News on GALT
Galectin Therapeutics to Present at the 2025 MASH-TAG Conference

Jan 10, 2025, 8:00 AM EST - 10 months ago

Galectin Therapeutics to Present at the 2025 MASH-TAG Conference


Galectin Therapeutics to Present in Upcoming Conferences

Oct 14, 2022, 8:00 AM EDT - 3 years ago

Galectin Therapeutics to Present in Upcoming Conferences


Galectin: Ability To Potentially Target Unmet Medical Need

Jul 11, 2022, 4:16 PM EDT - 3 years ago

Galectin: Ability To Potentially Target Unmet Medical Need


dmacw
dmacw Oct. 25 at 11:45 PM
$GALT When does the SEC embargo come off?
0 · Reply
ThomasLD
ThomasLD Oct. 25 at 7:22 PM
$GALT Great summary from Expharm. @beacher @Expharmaguy They will definitely meet with FDA per CFO Jack C. This company will likely be sold eventually. Just HOLD your shares if you already bought.
0 · Reply
beacher
beacher Oct. 25 at 5:20 PM
$GALT Hey all. I’ve heard some buzz about a potential buyout, which is why I’m digging into this. But based on the 10-Q for the quarter ended June 30, 2025, and the 2025 Proxy Statement, there’s no hint of a buyout. The financials show a cash balance of $13.771K and ongoing R&D expenses, while the Proxy focuses on the virtual annual meeting and routine shareholder votes. Now, regarding the vesting details for those 504,000 RSUs granted to employees: They’ll vest 100% either when the company enters a partnership or by December 31, 2025—whichever comes first! So the filing is suggesting they’re planning for the year-end vesting unless a partnership speeds things up. It’s a great incentive for the crew, but no immediate deal seems on the horizon! Despite that, it seems GLAT is an interesting investment - I´ll put it on my list.
2 · Reply
th3_fail_k1ng
th3_fail_k1ng Oct. 25 at 4:03 PM
$GALT well that's interesting, I just realized that astrazeneca's CEO, their mash division head, and an AstraZeneca headhunter have been liking our CMOS posts since the Koh conference. They have the money to buy us and they're headquartered in the EU as well and they hit above their weight class for buyouts? Plenty of options @gscdefense
2 · Reply
LiquidThetaLEAPS
LiquidThetaLEAPS Oct. 25 at 2:49 PM
LiquidTheta® LEAPS LIVE Actionable Alert Asset: $GALT Current Share Price: $5.23 Contracts: $GALT January 15, 2027 $8 Calls Scale in: $2.16- $2.64 Scale out: $3.36-$4.32 Can Easily Capture: 60% ROI Blended DTE: 447 Days | Join Elites here: https://liquidtheta.com
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Oct. 25 at 1:49 PM
Enter: $GALT Calls Strike Price: $8 Expiry Date: NOV 21 2025 Buy in Price: $0.22 - $0.25 Sell Price: $0.33 Profit : +49% (Turn every $1 into $1.49) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us/
0 · Reply
MoneyInc
MoneyInc Oct. 25 at 12:45 PM
$GALT AASLD approaches. End of year approaches. Get ready to absolutely rip!!
0 · Reply
ThomasLD
ThomasLD Oct. 25 at 12:21 PM
$GALT Since Belapectin is so complex to bid on, I am wondering we may get cash plus CVR for $18B x 2 ~ $36B?
1 · Reply
Indibviduate1
Indibviduate1 Oct. 25 at 7:42 AM
$GALT Interesting to note that Nordic bioscience supported Novo Nordisk by measuring fibroblast activity via pro c3. Wonder if they’re doing the same for us. “Nordic Bioscience would like to congratulate Novo Nordisk for the FDA approval of the first GLP-1 based therapy, semaglutide, for the treatment of adult patients living with MASH. We at Nordic Bioscience are proud to have supported the phase III “ESSENCE” trial, measuring our fibroblast activity marker, PRO-C3 in our Copenhagen based CAP/CLIA-certified laboratory. The “ESSENCE” trial presented data showing that semaglutide was able to reduce PRO-C3 by 17% compared to placebo treated patients. This is also an opportune time, as we are hosting a webinar on PRO-C3 that will delve into the PRO-C3 journey, its use cases, and its effect on world leading clinical trials.”
1 · Reply
Indibviduate1
Indibviduate1 Oct. 25 at 6:55 AM
$GALT so Nordic says that deactivating fibroblasts can significantly improve clinical outcomes for over 100 diseases. Well inhibiting galectin 3 is a proven way to deactivate fibroblasts. Do we have an incredibly valuable drug here for multiple applications?
2 · Reply
th3_fail_k1ng
th3_fail_k1ng Oct. 25 at 4:35 AM
$GALT coming soon to an AASLD Theater near you
0 · Reply
johnhankowitz
johnhankowitz Oct. 25 at 4:34 AM
$GALT Writing has been on the wall…
1 · Reply
Indibviduate1
Indibviduate1 Oct. 25 at 4:22 AM
2 · Reply
Indibviduate1
Indibviduate1 Oct. 25 at 4:20 AM
$GALT Galectin 3 and fibroblast activity.
0 · Reply
Indibviduate1
Indibviduate1 Oct. 25 at 4:16 AM
$GALT I wonder which clinical outcomes they might be linking?
0 · Reply
th3_fail_k1ng
th3_fail_k1ng Oct. 25 at 4:08 AM
$GALT I f*cking KNEW IT! DUDE IS ONE OF THE BIG D*CK KNOWN HEAD PHARMA NEGOTIATORS IN THE EU!
1 · Reply
drumbabydrum
drumbabydrum Oct. 25 at 3:19 AM
$GALT new short report report shows an additional $170K short shares added. Crazy how the price keeps ticking up even with increased shorted shares. Makes me happy 😁
0 · Reply
th3_fail_k1ng
th3_fail_k1ng Oct. 25 at 2:36 AM
$GALT GTFO here.....again with a 💡 what idea do you have this time Mr top negotiations expert in the German speaking world? First the koh conference and now dark horse pop up on the aasld meeting announcement..you definitely we're there a week ago when I looked. Someone has him watching us I'd bet my butt on it.
1 · Reply
th3_fail_k1ng
th3_fail_k1ng Oct. 25 at 2:04 AM
$GALT when our CMO knows more about your presentation than your CEO....and ahead of your own the official announcement 😉
3 · Reply
ThomasLD
ThomasLD Oct. 25 at 1:14 AM
$GALT 💯💯💯 1) Who is our competitor for F4 patients? None. 2) Does the company plan to GIA? No. 3) Are they looking for a partner? Yes. 4) Is Belapectin safe to take? Yes. 5) Belapectin if approved = blockbuster drug = BO! 6) 35% of 1.7m patients ramp up sales x$30K per treatment ~ $18B / 0.11925 ~ $150+ BO! 7) So, final BO price will likely be at least $100+ prior to short squeeze!🌙
1 · Reply
ThomasLD
ThomasLD Oct. 25 at 12:56 AM
$GALT 10x fund is not an insider. Selling 50,000 shares is nothing.
1 · Reply
KungFuJones
KungFuJones Oct. 25 at 12:26 AM
$GALT And just like that, another Form 4 from 10X.
1 · Reply